Updates

Cohort - Shares hit 853p

July 2024

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

The September 2023 issue of The Momentum Investor is proving to be an absolute ripper with main write-up DX (written at 36p) and Tyman (at 299.5p) succumbing to take-overs at 48.5p and 400p, respectively, while Cohort (the second main write-up at 516p) recently soared to 853p. Having earlier wowed investors with the largest contract win in its history, Cohort’s FY24 year-end update has now said performance is slightly ahead of expectations. With a robust book to bill ratio of 1.9x, Cohort delivered a very strong order intake of c. £387m (FY’23: £218m) through the year resulting in another record closing order book of around £518m (FY’23: £329m). This order book underpins 90% of current year revenue forecasts just one month into th ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Bloomsbury - Record acquisition; Singer’s target 780p

Sanderson

Cohort - Shares hit high of 1086p after acquisition (January 2025)

Cohort - Shares hit record high of 950p (November 2024)

Cohort - Path to mid teens EBT margins (from 10.4%) not in forecasts (September 2024)

Cohort - Shares up 170p in ‘24 after huge contract win (May 2024)

Cohort - In-year order intake 1.3x turnover (February 2024)

Cohort - Exciting play on growing defence spend (September 2023)

Cohort - Leader in defence technical services with eye on acquisitions (June 2006)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X